サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1706776

副腎白質ジストロフィー治療薬市場：世界の産業分析、規模、シェア、成長、動向、2025-2035年予測

Adrenoleukodystrophy Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

出版日
ページ情報
英文 210 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
副腎白質ジストロフィー治療薬市場：世界の産業分析、規模、シェア、成長、動向、2025-2035年予測
出版日: 2025年02月11日
発行: Transparency Market Research
ページ情報: 英文 210 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

副腎白質ジストロフィー治療薬市場- 調査範囲

TMRの調査レポート「世界の副腎白質ジストロフィー治療薬市場」は、2025年から2035年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2025年を基準年、2035年を予測年として、2019年から2035年までの世界の副腎白質ジストロフィー治療薬市場の収益と予測を提供します。また、2025年から2035年までの世界の副腎白質ジストロフィー治療薬市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、副腎白質ジストロフィー治療薬市場を推察しました。

市場スナップショット
2024年の市場規模 5億1,940万米ドル
2035年の市場規模 23億米ドル
CAGR 13.9%

当レポートでは、世界の副腎白質ジストロフィー治療薬市場の競合情勢について調査しています。世界の副腎白質ジストロフィー治療薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTが本レポートで紹介されている世界の副腎白質ジストロフィー治療薬市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー： 世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の副腎白質ジストロフィー治療薬市場の市場分析と予測, 2020-2035年

第5章 主要洞察

  • パイプライン分析
  • 地域/国別の疾患有病率と発症率
  • 主要な業界イベント（合併、買収、提携、コラボレーションなど）
  • ポーターのファイブフォース分析
  • PESTEL分析
  • 地域/国別の規制シナリオ
  • 地域/国別の償還シナリオ
  • 治療の選択肢とアルゴリズム
  • 新規市場参入者のための市場開拓戦略

第6章 世界の市場分析と予測：薬剤の種類別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：薬剤の種類別, 2020-2035年
    • 遺伝子治療
    • その他
  • 薬剤の種類別の市場の魅力

第7章 世界の市場分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：投与経路別, 2020-2035年
    • 経口
    • 非経口
  • 投与経路別の市場の魅力

第8章 世界の市場分析と予測：適応症別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：適応症別, 2020-2035年
    • 小児脳副腎白質ジストロフィー
    • アジソン病
    • 副腎脊髄ニューロパチー
  • 適応症別の市場の魅力

第9章 世界の市場分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：流通チャネル別, 2020-2035年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 流通チャネル別市場の魅力

第10章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 地域別市場の魅力

第11章 北米の市場分析と予測

  • 米国
  • カナダ

第12章 欧州の市場分析と予測

  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州地域

第13章 アジア太平洋地域の市場分析と予測

  • 中国
  • インド
  • 日本
  • オーストラリアとニュージーランド
  • その他アジア太平洋地域

第14章 ラテンアメリカの市場分析と予測

  • ブラジル
  • メキシコ
  • その他ラテンアメリカ地域

第15章 中東・アフリカの市場分析と予測

  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

第16章 競合情勢

  • 市場企業-競合マトリックス（企業階層別・規模別）
  • 市場シェア分析企業別（2024年）
  • 企業プロファイル
    • Minoryx Therapeutics
    • Bluebird Bio
    • Nutricia
    • Poxel SA
    • Orpheris, Inc.
    • MedDay Pharmaceuticals
    • Other Prominent Players
図表

List of Tables

  • Table 01: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2020-2035
  • Table 02: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2020-2035
  • Table 03: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Indication, 2020-2035
  • Table 04: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, By Distribution Channel, 2020-2035
  • Table 05: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, By Region, 2020-2035
  • Table 06: North America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Country, 2020-2035
  • Table 07: North America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2020-2035
  • Table 08: North America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2020-2035
  • Table 09: North America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Indication, 2020-2035
  • Table 10: North America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, By Distribution Channel, 2020-2035
  • Table 11: Europe - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Country, 2020-2035
  • Table 12: North America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2020-2035
  • Table 13: North America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2020-2035
  • Table 14: North America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Indication, 2020-2035
  • Table 15: Europe - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, By Distribution Channel, 2020-2035
  • Table 16: Asia Pacific - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Country, 2020-2035
  • Table 17: Asia Pacific - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2020-2035
  • Table 18: Asia Pacific - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2020-2035
  • Table 19: Asia Pacific - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Indication, 2020-2035
  • Table 20: Asia Pacific - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, By Distribution Channel, 2020-2035
  • Table 21: Latin America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Country, 2020-2035
  • Table 22: Latin America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, By Drug Type, 2020-2035
  • Table 23: Latin America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2020-2035
  • Table 24: Latin America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Indication, 2020-2035
  • Table 25: Latin America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, By Distribution Channel, 2020-2035
  • Table 26: Middle East & Africa - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Country, 2020-2035
  • Table 27: Middle East & Africa - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, By Drug Type, 2020-2035
  • Table 28: Latin America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2020-2035
  • Table 29: Latin America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, by Indication, 2020-2035
  • Table 30: Middle East & Africa - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, By Distribution Channel, 2020-2035

List of Figures

  • Figure 01: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 02: Global Adrenoleukodystrophy Drugs Market Value Share, by Drug Type, 2024
  • Figure 03: Global Adrenoleukodystrophy Drugs Market Value Share, by Route of Administration, 2024
  • Figure 04: Global Adrenoleukodystrophy Drugs Market Value Share, by Indication, 2024
  • Figure 05: Global Adrenoleukodystrophy Drugs Market Value Share, by Distribution Channel, 2024
  • Figure 06: Global Adrenoleukodystrophy Drugs Market Value Share, by Region, 2024
  • Figure 07: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, By Drug Type, 2024 and 2035
  • Figure 08: Global Adrenoleukodystrophy Drugs Market Share Analysis, By Drug Type, 2024
  • Figure 09: Global Adrenoleukodystrophy Drugs Market Share Analysis, By Drug Type, 2035
  • Figure 10: Global Adrenoleukodystrophy Drugs Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 11: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn), by Gene Therapy, 2020-2035
  • Figure 12: Global Adrenoleukodystrophy Drugs Market Value Share Analysis, by Gene Therapy, 2024 and 2035
  • Figure 13: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn), by Others, 2020-2035
  • Figure 14: Global Adrenoleukodystrophy Drugs Market Value Share Analysis, by Others, 2024 and 2035
  • Figure 15: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 16: Global Adrenoleukodystrophy Drugs Market Share Analysis, By Route of Administration, 2024
  • Figure 17: Global Adrenoleukodystrophy Drugs Market Share Analysis, By Route of Administration, 2035
  • Figure 18: Global Adrenoleukodystrophy Drugs Market Attractiveness Analysis, By Route of Administration, 2025-2035
  • Figure 19: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn), by Oral, 2020-2035
  • Figure 20: Global Adrenoleukodystrophy Drugs Market Value Share Analysis, by Oral, 2024 and 2035
  • Figure 21: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn), by Parenteral, 2020-2035
  • Figure 22: Global Adrenoleukodystrophy Drugs Market Value Share Analysis, by Parenteral, 2024 and 203531
  • Figure 23: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, By Indication, 2024 and 2035
  • Figure 24: Global Adrenoleukodystrophy Drugs Market Share Analysis, By Indication, 2024
  • Figure 25: Global Adrenoleukodystrophy Drugs Market Share Analysis, By Indication, 2035
  • Figure 26: Global Adrenoleukodystrophy Drugs Market Attractiveness Analysis, By Indication, 2025-2035
  • Figure 27: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn), by Childhood cerebral adrenoleukodystrophy, 2020-2035
  • Figure 28: Global Adrenoleukodystrophy Drugs Market Value Share Analysis, by Childhood cerebral adrenoleukodystrophy, 2024 and 2035
  • Figure 29: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn), by Addison's disease, 2020-2035
  • Figure 30: Global Adrenoleukodystrophy Drugs Market Value Share Analysis, by Addison's disease, 2024 and 2035
  • Figure 31: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn), by Adrenomyeloneuropathy, 2020-2035
  • Figure 32: Global Adrenoleukodystrophy Drugs Market Value Share Analysis, by Adrenomyeloneuropathy, 2024 and 2035
  • Figure 33: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 34: Global Adrenoleukodystrophy Drugs Market Share Analysis, By Distribution Channel, 2024
  • Figure 35: Global Adrenoleukodystrophy Drugs Market Share Analysis, By Distribution Channel, 2035
  • Figure 36: Global Adrenoleukodystrophy Drugs Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 37: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn), by Hospital Pharmacies, 2020-2035
  • Figure 38: Global Adrenoleukodystrophy Drugs Market Value Share Analysis, by Hospital Pharmacies, 2024 and 2035
  • Figure 39: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn), by Retail Pharmacies, 2020-2035
  • Figure 40: Global Adrenoleukodystrophy Drugs Market Value Share Analysis, by Retail Pharmacies, 2024 and 2035
  • Figure 41: Global Adrenoleukodystrophy Drugs Market Value (US$ Mn), by Online Pharmacies, 2020-2035
  • Figure 42: Global Adrenoleukodystrophy Drugs Market Value Share Analysis, by Online Pharmacies, 2024 and 2035
  • Figure 43: Global Adrenoleukodystrophy Drugs Market Value Share Analysis, by Region, 2024 and 2035
  • Figure 44: Global Adrenoleukodystrophy Drugs Market Share Analysis, by Region, 2024
  • Figure 45: Global Adrenoleukodystrophy Drugs Market Share Analysis, by Region, 2035
  • Figure 46: Global Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Region, 2025-2035
  • Figure 47: North America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2035
  • Figure 48: North America - Adrenoleukodystrophy Drugs Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 49: North America - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 50: North America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2024 and 2035
  • Figure 51: North America - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 52: North America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Route of Administration, 2024 and 2035
  • Figure 53: North America - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Route of Administration, 2025-2035
  • Figure 54: North America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Indication, 2024 and 2035
  • Figure 55: North America - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Indication, 2025-2035
  • Figure 56: North America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 57: North America - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 58: Europe - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2035
  • Figure 59: Europe - Adrenoleukodystrophy Drugs Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 60: Europe - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 61: Europe - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2024 and 2035
  • Figure 62: Europe - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 63: Europe - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Route of Administration, 2024 and 2035
  • Figure 64: Europe - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Route of Administration, 2025-2035
  • Figure 65: Europe - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Indication, 2024 and 2035
  • Figure 66: Europe - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Indication, 2025-2035
  • Figure 67: Europe - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 68: Europe - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 69: Asia Pacific - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2035
  • Figure 70: Asia Pacific - Adrenoleukodystrophy Drugs Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 71: Asia Pacific - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 72: Asia Pacific - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2024 and 2035
  • Figure 73: Asia Pacific - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 74: Asia Pacific - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Route of Administration, 2024 and 2035
  • Figure 75: Asia Pacific - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Route of Administration, 2025-2035
  • Figure 76: Asia Pacific - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Indication, 2024 and 2035
  • Figure 77: Asia Pacific - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Indication, 2025-2035
  • Figure 78: Asia Pacific - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 79: Asia Pacific - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 80: Latin America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2035
  • Figure 81: Latin America - Adrenoleukodystrophy Drugs Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 82: Latin America - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 83: Latin America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2024 and 2035
  • Figure 84: Latin America - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 85: Latin America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Route of Administration, 2024 and 2035
  • Figure 86: Latin America - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Route of Administration, 2025-2035
  • Figure 87: Latin America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Indication, 2024 and 2035
  • Figure 88: Latin America - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Indication, 2025-2035
  • Figure 89: Latin America - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 90: Latin America - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 91: Middle East & Africa - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2035
  • Figure 92: Middle East & Africa - Adrenoleukodystrophy Drugs Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 93: Middle East & Africa - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 94: Middle East & Africa - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2024 and 2035
  • Figure 95: Middle East & Africa - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 96: Middle East & Africa - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Route of Administration, 2024 and 2035
  • Figure 97: Middle East & Africa - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Route of Administration, 2025-2035
  • Figure 98: Middle East & Africa - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Indication, 2024 and 2035
  • Figure 99: Middle East & Africa - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Indication, 2025-2035
  • Figure 100: Middle East & Africa - Adrenoleukodystrophy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 101: Middle East & Africa - Adrenoleukodystrophy Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
目次
Product Code: TMRGL86448

Adrenoleukodystrophy Drugs Market - Scope of Report

TMR's report on the global adrenoleukodystrophy drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global adrenoleukodystrophy drugs market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global adrenoleukodystrophy drugs market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the adrenoleukodystrophy drugs market.

Market Snapshot
Market Value in 2024US$ 519.4 Mn
Market Value in 2035US$ 2.3 Bn
CAGR13.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global adrenoleukodystrophy drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global adrenoleukodystrophy drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global adrenoleukodystrophy drugs market.

The report delves into the competitive landscape of the global adrenoleukodystrophy drugs market. Key players operating in the global adrenoleukodystrophy drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global adrenoleukodystrophy drugs market profiled in this report.

Key Questions Answered in Global adrenoleukodystrophy drugs Market Report:

  • What is the sales/revenue generated by adrenoleukodystrophy drugs across all regions during the forecast period?
  • What are the opportunities in the global adrenoleukodystrophy drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Adrenoleukodystrophy Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global adrenoleukodystrophy drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global adrenoleukodystrophy drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global adrenoleukodystrophy drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Adrenoleukodystrophy Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Adrenoleukodystrophy Drugs Market Analysis and Forecasts, 2020-2035
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Disease Prevalence & Incidence Rate by Region/Countries
  • 5.3. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
  • 5.4. PORTER's Five Forces Analysis
  • 5.5. PESTEL Analysis
  • 5.6. Regulatory Scenario By Region/Countries
  • 5.7. Reimbursement Scenario By Region/Countries
  • 5.8. Treatment Options & Algorithm
  • 5.9. Go-to-Market Strategy for New Market Entrants

6. Global Adrenoleukodystrophy Drugs Market Analysis and Forecasts, By Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Drug Type, 2020-2035
    • 6.3.1. Gene Therapy
    • 6.3.2. Others
  • 6.4. Market Attractiveness By Drug Type

7. Global Adrenoleukodystrophy Drugs Market Analysis and Forecasts, By Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Route of Administration, 2020-2035
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Attractiveness By Route of Administration

8. Global Adrenoleukodystrophy Drugs Market Analysis and Forecasts, By Indication

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Indication , 2020-2035
    • 8.3.1. Childhood cerebral adrenoleukodystrophy
    • 8.3.2. Addison's disease
    • 8.3.3. Adrenomyeloneuropathy
  • 8.4. Market Attractiveness By Indication

9. Global Adrenoleukodystrophy Drugs Market Analysis and Forecasts, By Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By Distribution Channel , 2020-2035
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness By Distribution Channel

10. Global Adrenoleukodystrophy Drugs Market Analysis and Forecasts, By Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Region

11. North America Adrenoleukodystrophy Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Drug Type, 2020-2035
    • 11.2.1. Gene Therapy
    • 11.2.2. Others
  • 11.3. Market Value Forecast By Route of Administration, 2020-2035
    • 11.3.1. Oral
    • 11.3.2. Parenteral
  • 11.4. Market Value Forecast By Indication , 2020-2035
    • 11.4.1. Childhood cerebral adrenoleukodystrophy
    • 11.4.2. Addison's disease
    • 11.4.3. Adrenomyeloneuropathy
  • 11.5. Market Value Forecast By Distribution Channel , 2020-2035
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast By Country, 2020-2035
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Type
    • 11.7.2. By Route of Administration
    • 11.7.3. By Indication
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country

12. Europe Adrenoleukodystrophy Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Drug Type, 2020-2035
    • 12.2.1. Gene Therapy
    • 12.2.2. Others
  • 12.3. Market Value Forecast By Route of Administration, 2020-2035
    • 12.3.1. Oral
    • 12.3.2. Parenteral
  • 12.4. Market Value Forecast By Indication , 2020-2035
    • 12.4.1. Childhood cerebral adrenoleukodystrophy
    • 12.4.2. Addison's disease
    • 12.4.3. Adrenomyeloneuropathy
  • 12.5. Market Value Forecast By Distribution Channel , 2020-2035
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast By Country/Sub-region, 2020-2035
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Type
    • 12.7.2. By Route of Administration
    • 12.7.3. By Indication
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Adrenoleukodystrophy Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Drug Type, 2020-2035
    • 13.2.1. Gene Therapy
    • 13.2.2. Others
  • 13.3. Market Value Forecast By Route of Administration, 2020-2035
    • 13.3.1. Oral
    • 13.3.2. Parenteral
  • 13.4. Market Value Forecast By Indication , 2020-2035
    • 13.4.1. Childhood cerebral adrenoleukodystrophy
    • 13.4.2. Addison's disease
    • 13.4.3. Adrenomyeloneuropathy
  • 13.5. Market Value Forecast By Distribution Channel , 2020-2035
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast By Country/Sub-region, 2020-2035
    • 13.6.1. China
    • 13.6.2. India
    • 13.6.3. Japan
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Type
    • 13.7.2. By Route of Administration
    • 13.7.3. By Indication
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country/Sub-region

14. Latin America Adrenoleukodystrophy Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Drug Type, 2020-2035
    • 14.2.1. Gene Therapy
    • 14.2.2. Others
  • 14.3. Market Value Forecast By Route of Administration, 2020-2035
    • 14.3.1. Oral
    • 14.3.2. Parenteral
  • 14.4. Market Value Forecast By Indication , 2020-2035
    • 14.4.1. Childhood cerebral adrenoleukodystrophy
    • 14.4.2. Addison's disease
    • 14.4.3. Adrenomyeloneuropathy
  • 14.5. Market Value Forecast By Distribution Channel , 2020-2035
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast By Country/Sub-region, 2020-2035
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Type
    • 14.7.2. By Route of Administration
    • 14.7.3. By Indication
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Adrenoleukodystrophy Drugs Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Drug Type, 2020-2035
    • 15.2.1. Gene Therapy
    • 15.2.2. Others
  • 15.3. Market Value Forecast By Route of Administration, 2020-2035
    • 15.3.1. Oral
    • 15.3.2. Parenteral
  • 15.4. Market Value Forecast By Indication , 2020-2035
    • 15.4.1. Childhood cerebral adrenoleukodystrophy
    • 15.4.2. Addison's disease
    • 15.4.3. Adrenomyeloneuropathy
  • 15.5. Market Value Forecast By Distribution Channel , 2020-2035
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Retail Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast By Country/Sub-region, 2020-2035
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Drug Type
    • 15.7.2. By Route of Administration
    • 15.7.3. By Indication
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2. Market Share Analysis By Company (2024)
  • 16.3. Company Profiles
    • 16.3.1. Minoryx Therapeutics
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Financial Overview
      • 16.3.1.3. Product Portfolio
      • 16.3.1.4. Business Strategies
      • 16.3.1.5. Recent Developments
    • 16.3.2. Bluebird Bio
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Financial Overview
      • 16.3.2.3. Product Portfolio
      • 16.3.2.4. Business Strategies
      • 16.3.2.5. Recent Developments
    • 16.3.3. Nutricia
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Financial Overview
      • 16.3.3.3. Product Portfolio
      • 16.3.3.4. Business Strategies
      • 16.3.3.5. Recent Developments
    • 16.3.4. Poxel SA
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Financial Overview
      • 16.3.4.3. Product Portfolio
      • 16.3.4.4. Business Strategies
      • 16.3.4.5. Recent Developments
    • 16.3.5. Orpheris, Inc.
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Financial Overview
      • 16.3.5.3. Product Portfolio
      • 16.3.5.4. Business Strategies
      • 16.3.5.5. Recent Developments
    • 16.3.6. MedDay Pharmaceuticals
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Financial Overview
      • 16.3.6.3. Product Portfolio
      • 16.3.6.4. Business Strategies
      • 16.3.6.5. Recent Developments
    • 16.3.7. Other Prominent Players
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Financial Overview
      • 16.3.7.3. Product Portfolio
      • 16.3.7.4. Business Strategies
      • 16.3.7.5. Recent Developments